Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

36.02 -0.59 (-1.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Indivior Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
What to Know About This Fund's $74.8 Million Indivior Sale ↗
Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200% ↗
Indivior develops buprenorphine-based therapies for opioid dependence, serving healthcare providers and treatment centers worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund's $61.5 Million Exit From Ecovyst Amid a 75% Stock Rally ↗
Ecovyst delivers catalysts and sulfuric acid services to global refining and chemical industries with advanced process solutions. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge ↗
Via Chartmill
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Shows High Growth Momentum and Technical Breakout Potential ↗
Via Chartmill
News headline image
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Participate in Upcoming Investor Conferences
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally ↗
Indivior develops proprietary treatments for opioid dependence, generating revenue from specialty pharmaceuticals across global markets. 
Via The Motley Fool
Topics Regulatory Compliance
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Surpasses Q4 2025 Estimates and Provides Strong 2026 Outlook ↗
Via Chartmill
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Setup Case ↗
Via Chartmill
News headline image
Indivior Announces $175 Million Accelerated Share Repurchase
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior (INDV) Q1 2026 Earnings Transcript ↗
Indivior (INDV) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior Announces Proposed Convertible Senior Notes Offering
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Divisadero Dumps Stride Stock ↗
Stride delivers technology-driven education solutions for K–12 and adult learners, serving schools, districts, and employers nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Indivior (INDV) Q4 2025 Earnings Call Transcript ↗
Indivior (INDV) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Indivior to Participate in Upcoming Investor Conferences
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Vistance Networks Stock Up 250%. Here's Why a $40 Million Position Signals a Post-Divestiture Bet ↗
Vistance Networks delivers connectivity and network solutions for telecom, data centers, and enterprise clients worldwide. 
Via The Motley Fool
News headline image
Array Stock Down 25%, But This $17.3 Million Buy Signals Confidence Amid Big Revenue Growth ↗
Array Digital Infrastructure delivers wireless services and device sales to consumers, businesses, and government clients nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Enviri Stock Up 120% as $43 Million Buy Makes It a Top Holding in This Portfolio ↗
Enviri delivers environmental and specialty waste solutions for industrial clients through long-term contracts and value-added products. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Integer Stock Down 38%, but One Fund Just Bet $40 Million on a Turnaround ↗
Integer Holdings supplies medical device components and finished products to major OEMs in cardiac, neuro, and surgical markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.